Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/35933572/ below:

Trends in breast and prostate cancer screening and diagnostic procedures during the COVID-19 pandemic in central Massachusetts

Affiliations

• ¹ The Meyers Health Care Institute, A Joint Endeavor of the University of Massachusetts Chan Medical School, Fallon Health, and Reliant Medical Group, 365 Plantation Street Biotech 1, Suite 100, Worcester, MA, 01605, USA. mara.epstein@umassmed.edu.
• ² Division of Geriatric Medicine, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA. mara.epstein@umassmed.edu.
• ³ Reliant Medical Group, Worcester, MA, USA.
• ⁴ The Meyers Health Care Institute, A Joint Endeavor of the University of Massachusetts Chan Medical School, Fallon Health, and Reliant Medical Group, 365 Plantation Street Biotech 1, Suite 100, Worcester, MA, 01605, USA.
• ⁵ Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, USA.
• ⁶ Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Mongan Institute, Boston, MA, USA.
• ⁷ Department of Medicine, Harvard Medical School, Boston, MA, USA.
• ⁸ Division of Geriatric Medicine, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.

• PMID: 35933572
• PMCID: PMC9361987
• DOI: 10.1007/s10552-022-01616-4

Item in Clipboard

Mara M Epstein et al. Cancer Causes Control. 2022 Oct.

• ¹ The Meyers Health Care Institute, A Joint Endeavor of the University of Massachusetts Chan Medical School, Fallon Health, and Reliant Medical Group, 365 Plantation Street Biotech 1, Suite 100, Worcester, MA, 01605, USA. mara.epstein@umassmed.edu.
• ² Division of Geriatric Medicine, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA. mara.epstein@umassmed.edu.
• ³ Reliant Medical Group, Worcester, MA, USA.
• ⁴ The Meyers Health Care Institute, A Joint Endeavor of the University of Massachusetts Chan Medical School, Fallon Health, and Reliant Medical Group, 365 Plantation Street Biotech 1, Suite 100, Worcester, MA, 01605, USA.
• ⁵ Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, USA.
• ⁶ Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Mongan Institute, Boston, MA, USA.
• ⁷ Department of Medicine, Harvard Medical School, Boston, MA, USA.
• ⁸ Division of Geriatric Medicine, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.

• PMID: 35933572
• PMCID: PMC9361987
• DOI: 10.1007/s10552-022-01616-4

Item in Clipboard

Purpose: We calculated rates of breast and prostate cancer screening and diagnostic procedures performed during the COVID-19 pandemic through December 2021 compared to the same months in 2019 in a large healthcare provider group in central Massachusetts.

Methods: We included active patients of the provider group between January 2019 and December 2021 aged 30-85 years. Monthly rates of screening mammography and digital breast tomosynthesis, breast MRI, total prostate specific antigen (PSA), and breast or prostate biopsy per 1,000 people were compared by year overall, by age, and race/ethnicity. Completed procedures were identified by relevant codes in electronic health record data.

Results: Rates of screening mammography, tomosynthesis, and PSA testing reached the lowest levels in April-May 2020. Breast cancer screening rates decreased 43% in March and 99% in April and May 2020, compared to 2019. Breast cancer screening rates increased gradually beginning in June 2020 through 2021, although more slowly in Black and Hispanic women and in women aged 75-85. PSA testing rates decreased 34% in March, 78% in April, and 53% in May 2020, but rebounded to pre-pandemic levels by June 2020; trends were similar across groups defined by age and race/ethnicity.

Conclusion: The observed decline in two common screening procedures during the COVID-19 pandemic reflects the impact of the pandemic on cancer early detection and signals potential downstream effects on the prognosis of delayed cancer diagnoses. The slower rate of return for breast cancer screening procedures in certain subgroups should be investigated to ensure all women return for routine screenings.

Keywords: Breast cancer; COVID-19; Mammography; Prostate cancer; Prostate specific antigen; Screening.

© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

PubMed Disclaimer

The authors have no relevant financial or non-financial interests to disclose.

Overall rates of screening mammography…

Overall rates of screening mammography and tomosynthesis and Prostate Specific Antigen (PSA) testing…

Overall rates of screening mammography and tomosynthesis and Prostate Specific Antigen (PSA) testing per 1,000 people with COVID-19 monthly case counts in Massachusetts, January 2019–December 2021. Massachusetts COVID-19 case data acquired from the Massachusetts Department of Public Health COVID-19 Raw Data, accessed 17 September 2021 and 31 March 2022

Monthly rates of screening mammography…

Monthly rates of screening mammography and tomosynthesis testing per 1,000 women overall and…

Monthly rates of screening mammography and tomosynthesis testing per 1,000 women overall and by age group in a central Massachusetts medical provider group, 2019–2021

Rates of screening mammography and…

Rates of screening mammography and tomosynthesis per 1,000 women by race/ethnic group in…

Rates of screening mammography and tomosynthesis per 1,000 women by race/ethnic group in a central Massachusetts medical provider group, 2019–2021

Results of Interrupted Time Series…

Results of Interrupted Time Series analysis comparing trends in a overall mammography and…

Results of Interrupted Time Series analysis comparing trends in a overall mammography and tomosynthesis and b PSA testing rates between three time periods defined by the COVID-19 pandemic: January 2019–February 2020 (pre-pandemic), March 2020–June 2020 (initial pandemic shutdown), and July 2020–December 2021 (reopening)

Rates of PSA testing per…

Rates of PSA testing per 1,000 men overall and by age group in…

Rates of PSA testing per 1,000 men overall and by age group in a central Massachusetts medical provider group, 2019–2021

Rates of PSA testing per…

Rates of PSA testing per 1,000 men by race/ethnicity in a central Massachusetts…

Rates of PSA testing per 1,000 men by race/ethnicity in a central Massachusetts medical provider group, 2019–2021

• Patterns of Prostate-Specific Antigen Testing and Prostate Biopsies During the COVID-19 Pandemic.

  Kaufman HW, Chen Z, Niles JK, Radcliff J, Fesko Y. Kaufman HW, et al. JCO Clin Cancer Inform. 2021 Sep;5:1028-1033. doi: 10.1200/CCI.21.00074. JCO Clin Cancer Inform. 2021. PMID: 34648367

• Association of Cancer Screening Deficit in the United States With the COVID-19 Pandemic.

  Chen RC, Haynes K, Du S, Barron J, Katz AJ. Chen RC, et al. JAMA Oncol. 2021 Jun 1;7(6):878-884. doi: 10.1001/jamaoncol.2021.0884. JAMA Oncol. 2021. PMID: 33914015 Free PMC article.

• Are there regional tendencies toward controversial screening practices? A study of prostate and breast cancer screening in a Medicare population.

  Raffin E, Onega T, Bynum J, Austin A, Carmichael D, Bronner K, Goodney P, Hyams ES. Raffin E, et al. Cancer Epidemiol. 2017 Oct;50(Pt A):68-75. doi: 10.1016/j.canep.2017.07.015. Epub 2017 Aug 17. Cancer Epidemiol. 2017. PMID: 28822325

• Assessing the impact of the COVID-19 pandemic on breast cancer screening and diagnosis rates: A rapid review and meta-analysis.

  Ng JS, Hamilton DG. Ng JS, et al. J Med Screen. 2022 Dec;29(4):209-218. doi: 10.1177/09691413221101807. Epub 2022 May 20. J Med Screen. 2022. PMID: 35593115 Free PMC article. Review.

• A systematic review of the impact of the COVID-19 pandemic on breast cancer screening and diagnosis.

  Li T, Nickel B, Ngo P, McFadden K, Brennan M, Marinovich ML, Houssami N. Li T, et al. Breast. 2023 Feb;67:78-88. doi: 10.1016/j.breast.2023.01.001. Epub 2023 Jan 5. Breast. 2023. PMID: 36646004 Free PMC article. Review.

• Factors associated with non-adherence to dual-energy x-ray absorptiometry screening during the COVID-19 pandemic in an academic medical center.

  Shi Q, Cheah JT, Zai AH. Shi Q, et al. Arch Osteoporos. 2024 Jul 30;19(1):66. doi: 10.1007/s11657-024-01430-2. Arch Osteoporos. 2024. PMID: 39080113

1. 1. Massachusetts Department of Public Health. COVID-19 Response Reporting. COVID-19 Raw Data—Dec 13, 2020. https://www.mass.gov/info-details/covid-19-response-reporting#covid-19-d.... Accessed Dec 13 2020
2. 1. Sharpless NE. COVID-19 and cancer. Science. 2020;368:1290. doi: 10.1126/science.abd3377. - DOI - PubMed
3. 1. Sud A, Torr B, Jones ME, Broggio J, Scott S, Loveday C, et al. Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. Lancet Oncol. 2020;21:1035–1044. doi: 10.1016/S1470-2045(20)30392-2. - DOI - PMC - PubMed
4. 1. Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020;21:1023–1034. doi: 10.1016/S1470-2045(20)30388-0. - DOI - PMC - PubMed
5. 1. US Preventive Services Task Force. Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, et al. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA. 2018;319:1901–1913. doi: 10.1001/jama.2018.3710. - DOI - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3